iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma

被引：0
|
作者：
Shapiro, Roman M. [1 ]
Romee, Rizwan [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Div Transplantat & Cellular Therapies, Boston, MA 02215 USA
来源：
LANCET | 2025年 / 405卷 / 10473期
关键词：
D O I：
10.1016/S0140-6736(24)02524-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [41] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma
    Stock, Sophia
    Bucklein, Veit L.
    Blumenberg, Viktoria
    Magno, Giulia
    Emhardt, Alica-Joana
    Holzem, Alessandra M. E.
    dos Santos, David M. Cordas
    Schmidt, Christian
    Griesshammer, Stefanie
    Frolich, Lisa
    Kobold, Sebastian
    von Bergwelt-Baildon, Michael
    Rejeski, Kai
    Subklewe, Marion
    HEMASPHERE, 2025, 9 (01):
  • [42] Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
    Jain, Michael D.
    Zhao, Hua
    Atkins, Reginald
    Menges, Meghan A.
    Pope, Crystal R.
    Faramand, Rawan
    Lee, Sae Bom
    Boucher, Justin C.
    Kotani, Hiroshi
    Bachmeier, Christina A.
    Chavez, Julio
    Shah, Bijal
    Hussaini, Mohammad
    Gonzalez, Ricardo J.
    Mullinax, John E.
    Davila, Marco L.
    Locke, Frederick L.
    BLOOD, 2019, 134
  • [43] Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
    Maude, Shannon L.
    Barrett, David M.
    Ambrose, David E.
    Rheingold, Susan R.
    Aplenc, Richard
    Teachey, David T.
    Callahan, Colleen
    Barker, Christine S.
    Mudambi, Maya
    Shaw, Pamela A.
    Brogdon, Jennifer
    Young, Regina M.
    Scholler, John
    Loew, Andreas
    Marcucci, Katherine T.
    Finklestein, Jeffrey
    Kulikovskaya, Irina
    Nazimuddin, Farzana
    Zheng, Zhaohui
    Levine, Bruce L.
    Porter, David L.
    Lacey, Simon F.
    Melenhorst, Jan J.
    June, Carl H.
    Grupp, Stephan A.
    BLOOD, 2015, 126 (23)
  • [44] Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia
    Wang, Yiyun
    Wang, Linqin
    Shao, Mi
    He, Xiangjun
    Yue, Yanan
    Zhou, Yixuan
    Yang, Luhan
    Huang, He
    Hu, Yongxian
    BLOOD, 2022, 140 : 12685 - 12685
  • [45] CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma
    Yu, Qiuxia
    Gang, Daizi
    Wang, Jue
    Huang, Liang
    Li, Chunrui
    Zhang, Yicheng
    Zhou, Xiaoxi
    Cao, Yang
    BLOOD, 2023, 142
  • [46] A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
    Park, Jae H.
    Sauter, Craig S.
    Palomba, M. Lia
    Shah, Gunjan L.
    Dahi, Parastoo B.
    Lin, Richard J.
    Scordo, Michael
    Batlevi, Connie Lee
    Perales, Miguel-Angel
    Kane, Peter
    Afuye, Aishat Olaide
    Mead, Elena
    Santomasso, Bianca
    Halton, Elizabeth
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2021, 138
  • [47] A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
    Zhitao Ying
    Ting He
    Shanzhao Jin
    Xiaopei Wang
    Wen Zheng
    Ningjing Lin
    Meifeng Tu
    Yan Xie
    Lingyan Ping
    Weiping Liu
    Lijuan Deng
    Yanping Ding
    Xuelian Hu
    Bing Bu
    Xin'an Lu
    Yuqin Song
    Jun Zhu
    ChineseJournalofCancerResearch, 2022, 34 (01) : 53 - 67
  • [48] CAR-T Therapy for the Treatment of Relapsed/Refractory CD19 Positive Large B Cell Lymphoma: Canadian Real-World Evidence
    Tan, Xiu Xia Sherry
    Maltez, Melissa
    Mallick, Ranjeeta
    Hamelin, Linda
    McDiarmid, Sheryl
    Kennah, Michael
    Atkins, Harold
    Kekre, Natasha K.
    BLOOD, 2023, 142
  • [49] Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma
    Wang, Jiaxi
    Jiang, Yirong
    Luo, Min
    Lu, Wenyi
    He, Jixiang
    Zhang, Meng
    Yao, Zhuoxin
    Jin, Xin
    Xiao, Xia
    Chen, Jianhang
    Li, Guangchao
    Ding, Wen
    Zhou, Jie
    Zhang, Zhiyin
    Zhao, Mingfeng
    CURRENT CANCER DRUG TARGETS, 2024,
  • [50] A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
    Ying, Zhitao
    He, Ting
    Jin, Shanzhao
    Wang, Xiaopei
    Zheng, Wen
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Ping, Lingyan
    Liu, Weiping
    Deng, Lijuan
    Ding, Yanping
    Hu, Xuelian
    Bu, Bing
    Lu, Xin'an
    Song, Yuqin
    Zhu, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (01)
12345